Table 4.
15 Letter ETDRS Visual Acuity Changes in 3 Study Groups and the Natural History Cohort
|
Group 1: Chronic bilateral group
| |||||||
| Months | Study Eye | Fellow Eye | |||||
|
|
|||||||
| Followed | Dose | Worsened | Stable | Improved | Worsened | Stable | Improved |
|
| |||||||
| Nat Hx | 0 (0%) | 19 (79%) | 5 (21%) | 1 (4%) | 21 (88%) | 2 (8%) | |
| Low | 0 (0%) | 3 (100%) | 0 (0%) | 0 (0%) | 2 (67%) | 1 (33%) | |
| 12 | Medium | 0 (0%) | 2 (67%) | 1 (33%) | 0 (0%) | 2 (67%) | 1 (33%) |
| High | 0 (0%) | 1 (33%) | 2 (67%) | 0 (0%) | 2 (67%) | 1 (33%) | |
| Higher | 0 (0%) | 2 (100%) | 0 (0%) | 0 (0%) | 2 (100%) | 0 (0%) | |
|
| |||||||
| Nat Hx | 1 (5%) | 13 (68%) | 5 (26%) | 0 (0%) | 16 (84%) | 3 (16%) | |
| 24 | Low | 0 (0%) | 2 (67%) | 1 (33%) | 0 (0%) | 2 (67%) | 1 (33%) |
| Medium | 0 (0%) | 2 (67%) | 1 (33%) | 0 (0%) | 2 (67%) | 1 (33%) | |
| High | 0 (0%) | 1 (33%) | 2 (67%) | 0 (0%) | 2 (67%) | 1 (33%) | |
|
| |||||||
| Nat Hx | 0 (0%) | 9 (82%) | 2 (18%) | 0 (0%) | 10 (91%) | 1 (9%) | |
| 36 | Low | 0 (0%) | 2 (67%) | 1 (33%) | 0 (0%) | 2 (67%) | 1 (33%) |
| Medium | 0 (0%) | 2 (67%) | 1 (33%) | 0 (0%) | 2 (67%) | 1 (33%) | |
|
Group 2: Acute Bilateral group | |||||||
| Months | Study Eye | Fellow Eye | |||||
|
|
|||||||
| Followed | Dose | Worsened | Stable | Improved | Worsened | Stable | Improved |
|
| |||||||
| Nat Hx | 2 (22%) | 3 (33%) | 4 (44%) | 3 (33%) | 3 (33%) | 3 (33%) | |
| 12 | Low | 0 (0%) | 1 (33%) | 2 (67%) | 1 (33%) | 2 (67%) | 0 (0%) |
| Medium | 0 (0%) | 2 (100%) | 0 (0%) | 0 (0%) | 2 (100%) | 0 (0%) | |
| Higher | 1 (33%) | 2 (67%) | 0 (0%) | 2 (67%) | 1 (33%) | 0 (0%) | |
|
| |||||||
| Nat Hx | 1 (13%) | 4 (50%) | 3 (38%) | 3 (38%) | 3 (38%) | 2 (25%) | |
| 24 | Low | 0 (0%) | 0 (0%) | 3 (100%) | 0 (0%) | 1 (33%) | 2 (67%) |
| Medium | 0 (0%) | 2 (100%) | 0 (0%) | 0 (0%) | 2 (100%) | 0 (0%) | |
| Higher | 1 (33%) | 1 (33%) | 1 (33%) | 2 (67%) | 0 (0%) | 1 (33%) | |
|
| |||||||
| Nat Hx | 1 (14%) | 4 (57%) | 2 (29%) | 2 (29%) | 4 (57%) | 1 (14%) | |
| 36 | Low | 0 (0%) | 0 (0%) | 3 (100%) | 0 (0%) | 1 (33%) | 2 (67%) |
| Medium | 0 (0%) | 2 (100%) | 0 (0%) | 0 (0%) | 2 (100%) | 0 (0%) | |
|
Group 3: Unilateral Acute Group | |||||||
| Months | Study Eye | Fellow Eye | |||||
|
|
|||||||
| Followed | Dose | Worsened | Stable | Improved | Worsened | Stable | Improved |
|
| |||||||
| Nat Hx | 1 (50%) | 1 (50%) | 0 (0%) | 0 (0%) | 2 (100%) | 0 (0%) | |
| 12 | Low | 3 (100%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (67%) | 1 (33%) |
| Medium | 3 (100%) | 0 (0%) | 0 (0%) | 2 (67%) | 1 (33%) | 0 (0%) | |
| Higher | 2 (100%) | 0 (0%) | 1 (0%) | 1 (50%) | 1 (50%) | 0 (0%) | |
|
| |||||||
| Nat Hx | 1 (50%) | 1 (50%) | 0 (0%) | 0 (0%) | 1 (50%) | 1 (50%) | |
| 24 | Low | 3 (100%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (67%) | 1 (33%) |
| Medium | 3 (100%) | 0 (0%) | 0 (0%) | 2 (67%) | 1 (33%) | 0 (0%) | |
|
| |||||||
| Nat Hx | 0 (0%) | 1 (100%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (100%) | |
| 36 | Low | 3 (100%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (67%) | 1 (33%) |
| Medium | 3 (100%) | 0 (0%) | 0 (0%) | 2 (67%) | 1 (33%) | 0 (0%) | |
Nat Hx = Natural History